| 1 |
30663560 | Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice. | 2020 |
1 |
| 2 |
31880221 | Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis. | 2020 Jan |
2 |
| 3 |
33172034 | Pioglitazone Is Associated with Lower Major Adverse Cardiovascular and Cerebrovascular Events than DPP4-Inhibitors in Diabetic Patients with End-Stage Renal Disease: A Taiwan Nationwide Cohort Study, 2006-2016. | 2020 Nov 6 |
1 |
| 4 |
31087620 | Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes. | 2019 Sep |
1 |
| 5 |
29138876 | Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study. | 2018 Mar |
1 |
| 6 |
27429679 | The Influences of Withdrawal and Daily Dose Reduction of Pioglitazone on Metabolic Parameters in Patients With Type 2 Diabetes: A Retrospective Longitudinal Observational Study. | 2016 Aug |
2 |
| 7 |
24824197 | Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study. | 2014 Dec |
1 |
| 8 |
22192641 | Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers. | 2012 Jan |
1 |
| 9 |
21595275 | [A compounding agent of alogliptin and pioglitazone]. | 2011 May |
1 |
| 10 |
21651446 | Pioglitazone: a valuable component of combination therapy for type 2 diabetes mellitus. | 2011 Jul |
2 |
| 11 |
20875371 | Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers. | 2010 Oct |
1 |
| 12 |
20883052 | Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. | 2010 Oct 22 |
1 |
| 13 |
19259628 | DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy. | 2009 Mar |
1 |
| 14 |
18793589 | Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes. | 2008 Jul |
1 |